B
Blaise Genton
Researcher at University of Lausanne
Publications - 241
Citations - 10715
Blaise Genton is an academic researcher from University of Lausanne. The author has contributed to research in topics: Malaria & Population. The author has an hindex of 49, co-authored 226 publications receiving 9683 citations. Previous affiliations of Blaise Genton include West Health & University Hospital of Lausanne.
Papers
More filters
Journal ArticleDOI
Decreased In Vitro Susceptibility of Plasmodium falciparum Isolates to Artesunate, Mefloquine, Chloroquine, and Quinine in Cambodia from 2001 to 2007
Pharath Lim,Chansuda Wongsrichanalai,Pheaktra Chim,Nimol Khim,Saorin Kim,Sophy Chy,Rithy Sem,Sina Nhem,Poravuth Yi,Socheat Duong,Denis Mey Bouth,Blaise Genton,Hans-Peter Beck,Jean Gerard Gobert,William O. Rogers,Jean-Yves Coppée,Thierry Fandeur,Odile Mercereau-Puijalon,Pascal Ringwald,Jacques Le Bras,Frédéric Ariey +20 more
TL;DR: The GMIC50s of the four drugs tested increased significantly in eastern Cambodia during 2006 to 2007, which may signal deterioration of the efficacy of artesunate-mefloquine beyond the Cambodian-Thai border.
Journal ArticleDOI
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
Nicholas M. Anstey,Ric N. Price,Tme Davis,Harin Karunajeewa,Ivo Mueller,Umberto D'Alessandro,Achille Massougbodji,Frederic Nikiema,Jean-Bosco Ouédraogo,Halidou Tinto,Issaka Zongo,Albert Same-Ekobo,M Kone,H Menan,AO Toure,William Yavo,Poul-Erik Kofoed,Bereket Alemayehu,Daddi Jima,Elisabeth Baudin,Emmanuelle Espie,Carolyn Nabasumba,Loretxu Pinoges,Birgit Schramm,Michel Cot,Philippe Deloron,Jean-François Faucher,Jean-Paul Guthmann,Bertrand Lell,Steffen Borrmann,George O. Adjei,J Ursing,Emiliana Tjitra,Kevin Marsh,Judy Peshu,Elizabeth Juma,Bernhards Ogutu,Sabah A. Omar,Patrick Sawa,Ambrose O. Talisuna,Maniphone Khanthavong,M Mayxay,Paul N. Newton,Patrice Piola,Abdoulaye Djimde,Ogobara K. Doumbo,Bakary Fofana,Issaka Sagara,Quique Bassat,Raquel González,Clara Menéndez,Frank Smithuis,Teun Bousema,Piet A. Kager,P. F. Mens,Hdfh Schallig,I Van den Broek,M. van Vugt,Maman Laminou Ibrahim,Catherine O. Falade,Martin M Meremikwu,José Pedro Gil,Corine Karema,Ba,Babacar Faye,Oumar Faye,Gaye O,Jean Louis Ndiaye,Mbaye Pene,Doudou Sow,K Sylla,Rck Tine,Louis K. Penali,Karen I. Barnes,Lesley Workman,Angeles Lima,Ishag Adam,Nahla B Gadalla,Efm Malik,Anders Björkman,Andreas Mårtensson,Billy Ngasala,Lars Rombo,P Aliu,Stephan Duparc,Scott G. Filler,Blaise Genton,Eva Maria Hodel,Piero Olliaro,S Abdulla,Erasmus Kamugisha,Zulfiqarali Premji,Seif Shekalaghe,Elizabeth A. Ashley,Verena I. Carrara,Rose McGready,François Nosten,Abul Faiz,Sue J. Lee,Nicholas J. White,Arjen M. Dondorp,Jeff Smith,Joel Tarning,Jane Achan,Hasifa Bukirwa,Adoke Yeka,Emmanuel Arinaitwe,Sarah G. Staedke,Kamya,Fred Kironde,Chris Drakeley,Mary C. Oguike,Colin J. Sutherland,Francesco Checchi,Prabin Dahal,Jennifer A. Flegg,Philippe J Guerin,Clarissa Moreira,Christian Nsanzabana,Carol Hopkins Sibley,Kasia Stepniewska,Peter W. Gething,Si Hay,Brian Greenwood,Stephen A. Ward,P. A. Winstanley,Grant Dorsey,Bryan Greenhouse,P. Rosenthal,Anastasia Grivoyannis,Kamal Hamed,J Hwang,PS Kachur,Michael Nambozi +133 more
TL;DR: The recommended dose of artemether-lumefantrine provides reliable efficacy in most patients with uncomplicated malaria, however, therapeutic efficacy was lowest in young children from Asia and young underweight children from Africa; a higher dose regimen should be assessed in these groups.
Journal ArticleDOI
Dengue, Zika and chikungunya during pregnancy: pre- and post-travel advice and clinical management.
Manon Vouga,Yen-Chi Chiu,Léo Pomar,Sara V de Meyer,Sophie Masmejan,Blaise Genton,Didier Musso,David Baud,Milos Stojanov +8 more
TL;DR: Young adults of childbearing age and pregnant women are travelling more frequently to tropical areas, exposing them to specific arboviral infections such as dengue, zika and chikungunya viruses, which may impact ongoing and future pregnancies.
Journal ArticleDOI
Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose.
TL;DR: Delaying the booster dose up to 66 months after primary vaccination did not seem to influence the immunogenicity of the boosters, however, the recommended 6-12-month interval remains if detectable antibody titers are to be warranted constantly.
Journal ArticleDOI
Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
Abdunoor M. Kabanywanyi,Christian Lengeler,Prudensiana Kasim,Said King'eng'ena,Raymond G. Schlienger,Nathan Mulure,Blaise Genton +6 more
TL;DR: Adherence to the dosing regimen and timing of AL administration was very good and patients believed that AL was more effective than sulphadoxine-pyrimethamine (SP), which is likely to be helpful packaging, pictorial dosing instructions and patients' conviction that AL is effective.